Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Ductal Carcinoma in Situ
100%
Phase 1 Clinical Trial
100%
Breast Cancer
40%
Immunization
26%
Tumor
20%
Phase I Trial
13%
United States
13%
High Cost
13%
Patient Will
13%
Dose Finding
13%
Vaccination
13%
Cervical Cancer
6%
Phase Ib Trial
6%
Medical Community
6%
Effective Alternatives
6%
Clinical Trials
6%
Lung
6%
Institutional Review Board
6%
Aromatase Inhibitors
6%
Immune System
6%
Small Lesions
6%
High Dose
6%
Chemotherapy Treatment
6%
Cervical Abnormalities
6%
Risk Factors
6%
Ongoing Trials
6%
Adverse Health Effects
6%
Increased Incidence
6%
Host Immunity
6%
Less Invasive Approach
6%
Adverse Health
6%
Estrogen Receptor
6%
Surgical Removal
6%
Surgery Treatment
6%
Hormonal Therapy
6%
Persistence of Immunity
6%
Immunogenicity
6%
Safer Alternatives
6%
Uterus
6%
Every 2 weeks
6%
Mastectomy
6%
Overall Incidence
6%
Health Problems
6%
Clinical Testing
6%
Cancer Development
6%
Reduced Physical Activity
6%
Invasive Breast Cancer
6%
Early Breast Cancer
6%
Estrogen Antagonist
6%
Non-cancer
6%
System Protection
6%
Health Challenges
6%
Endometrial Cancer
6%
Older Women
6%
Early Risk
6%
Breast Cancer Patients
6%
Need for Surgery
6%
Blood Clot
6%
Small Deposits
6%
Chemotherapy
6%
HPV Oncoproteins
6%
Standard of Care
6%
Breast Cancer Research
6%
Lumpectomy
6%
Cancer Tumor
6%
Tumor Tissue
6%
Host Immune Defense
6%
Design Steps
6%
Natural Host
6%
Weight Gain Rate
6%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Intraductal Carcinoma
100%
Breast Cancer
60%
Malignant Neoplasm
26%
Neoplasm
20%
Vaccination
13%
Chemotherapy Regimens
13%
Diseases
13%
Tamoxifen
13%
Peptide
6%
Antiestrogen
6%
Aromatase Inhibitor
6%
Immunogenicity
6%
Phase I Trials
6%
Endometrium Cancer
6%
Estrogen Receptor
6%
Oncoprotein
6%
Uterine Cervix Cancer
6%
Natural Host
6%